

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 10, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 10, 2019**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware                      001-33357                      65-0643773**  
**(State or other jurisdiction) (Commission File Number) (IRS Employer)**

of incorporation)

Identification No.)

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel 20100  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. "

**Item 5.07 Submission of Matters to a Vote of Security Holders**

Protalix BioTherapeutics, Inc. (the “Company”) held a Special Meeting of Stockholders on January 10, 2019 (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares of the Company’s common stock, par value \$0.001 per share, authorized for issuance from 250,000,000 to 350,000,000. Set forth below are the number of votes cast for and against, and the number of abstentions, for the proposal.

Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares our common stock, par value \$0.001 per share, authorized for issuance from 250,000,000 to 350,000,000

For	Against	Abstain
74,755,268	14,044,511	373,156

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: January 10, 2019 By: /s/ Yossi Maimon  
Name: Yossi Maimon  
Title: Vice President and  
Chief Financial Officer